Hdmx Modulates the Outcome of P53 Activation in Human Tumor Cells
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
Tumors that express wild-type P53 provide a target for therapies designed to reactivate P53 function. This is supported by the potent activation of P53 in tumor cells by Nutlin, a cis-imidazoline that inhibits the Hdm2-P53 interaction. The efficacy of Hdm2.P53 antagonists could be compromised if they do not antagonize Hdmx, an Hdm2 homolog that inhibits P53 transactivation. We evaluated the role of Hdmx expression in sensitivity to Nutlin in a range of cancer cell lines. Nutlin reduced Hdmx levels in normal cells and some cancer cell lines, whereas other cancer cells were refractory to such down-regulation. Strikingly, Nutlin did not disrupt Hdmx.P53 complexes, and in cell lines where no Hdmx degradation occurred, Nutlin failed to induce apoptosis. shRNA-mediated reduction of Hdmx sensitized cells to apoptosis, but caspase-3 was neither required nor sufficient for Hdmx degradation or apoptosis. Our data imply that Hdmx is an important determinant of the outcome of P53 activation. Thus, targeting Hdmx may be a therapeutic strategy that complements drugs such as Nutlin.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“MDM4 amplification was even shown to reduce sensitivity of cells to Nutlin-3 [29–31].”
From Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2 -Amplified and TP53 Wild-type Glioblastomas (2016) · cites this paper as [30]
In the citing paper
“Although nutlin 3a and MI-219 robustly activate p53 in cancer cells with overexpressed MDM2, they do not consistently elicit p53-dependent effects in cancer cells that overexpress MDMX99–102.”
From MDM2, MDMX and p53 in oncogenesis and cancer therapy (2013) · cites this paper as [102]
Citations
Cites
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
TIGAR, a p53-Inducible Regulator of Glycolysis and Apoptosis
Bensaad, K., Tsuruta, A., Selak, M. A., Vidal, M. N. C., Nakano, K., Bartrons, R., Gottlieb, E., & Vousden, K. H. (2006) · Cell · doi:10.1016/j.cell.2006.05.036 · Cited by 2,019
Caspase-3 Is Required for DNA Fragmentation and Morphological Changes Associated with Apoptosis
Jänicke, R. U., Sprengart, M. L., Wati, M. R., & Porter, A. G. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.16.9357 · Cited by 1,953
Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53
de Oca Luna, R. M., Wagner, D. S., & Lozano, G. (1995) · Nature · doi:10.1038/378203a0 · Cited by 1,420
DRAM, a p53-Induced Modulator of Autophagy, Is Critical for Apoptosis
Crighton, D., Wilkinson, S., O'Prey, J., Syed, N., Smith, P., Harrison, P. R., Gasco, M., Garrone, O., Crook, T., & Ryan, K. M. (2006) · Cell · doi:10.1016/j.cell.2006.05.034 · Cited by 1,380
Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53
Jones, S. N., Roe, A. E., Donehower, L. A., & Bradley, A. (1995) · Nature · doi:10.1038/378206a0 · Cited by 1,280
Research works printed but not linked: 3
- Schwartzberg, 2006, J. Support. Oncol., 42, 3
- Finch, 2002, Cancer Res., 62, 3221
- Tian, 2006, Biochem. Biophys. Res. Commun., 2, 2
Cited by
Regulating the p53 pathway: in vitro hypotheses, in vivo veritas
Toledo, F., & Wahl, G. M. (2006) · Nature reviews. Cancer · doi:10.1038/nrc2012 · Cited by 1,286
Self-citationMDM2, MDMX and p53 in oncogenesis and cancer therapy
Wade, M., Li, Y.-C., & Wahl, G. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3430 · Cited by 1,279
Self-citationDrugging the p53 pathway: understanding the route to clinical efficacy
Khoo, K. H., Verma, C. S., & Lane, D. P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4236 · Cited by 719
Shangary, S., & Wang, S. (2009) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094723 · Cited by 623
Coping with stress: multiple ways to activate p53
Horn, H. F., & Vousden, K. H. (2007) · Oncogene · doi:10.1038/sj.onc.1210263 · Cited by 522
Targeting the MDM2-p53 Interaction for Cancer Therapy
Shangary, S., & Wang, S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5136 · Cited by 366
MDM4 is a key therapeutic target in cutaneous melanoma
Gembarska, A., Luciani, F., Fedele, C., Russell, E. A., Dewaele, M., Villar, S., Zwolinska, A., Haupt, S., de Lange, J., Yip, D., et al. (2012) · Nature Medicine · doi:10.1038/nm.2863 · Cited by 327
Clinical Overview of MDM2/X-Targeted Therapies
Burgess, A., Chia, K. M., Haupt, S., Thomas, D., Haupt, Y., & Lim, E. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00007 · Cited by 315
A Stapled p53 Helix Overcomes HDMX-Mediated Suppression of p53
Bernal, F., Wade, M., Godes, M., Davis, T. N., Whitehead, D. G., Kung, A. L., Wahl, G. M., & Walensky, L. D. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.024 · Cited by 285
Self-citationMDM2 and MDMX promote ferroptosis by PPARα-mediated lipid remodeling
Venkatesh, D., O'Brien, N. A., Zandkarimi, F., Tong, D. R., Stokes, M. E., Dunn, D. E., Kengmana, E. S., Aron, A. T., Klein, A. M., Csuka, J. M., et al. (2020) · Genes & Development · doi:10.1101/gad.334219.119 · Cited by 274
MDM2 and MDM4: p53 regulators as targets in anticancer therapy
Toledo, F., & Wahl, G. M. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.03.022 · Cited by 261
Self-citationActivation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization
Graves, B., Thompson, T., Xia, M., Janson, C., Lukacs, C., Deo, D., Di Lello, P., Fry, D., Garvie, C., Huang, K.-S., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203789109 · Cited by 230
“These results are in agreement with previously published data using RNA interference to address the role of MDMX in the response to nutlin (23, 28, 35).”
BackgroundResultEfficient p53 Activation and Apoptosis by Simultaneous Disruption of Binding to MDM2 and MDMX
Hu, B., Gilkes, D. M., & Chen, J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1140 · Cited by 213
Targeting Apoptosis Pathways for New Cancer Therapeutics
Bai, L., & Wang, S. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-010713-141310 · Cited by 176
“MDMX, which is not efficiently antagonized by nutlins or MI-219, has been proposed as a major determinant for drug resistance (88, 97).”
BackgroundPhan, J., Li, Z., Kasprzak, A., Li, B., Sebti, S., Guida, W., Schönbrunn, E., & Chen, J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.073056 · Cited by 173
Enge, M., Bao, W., Hedström, E., Jackson, S. P., Moumen, A., & Selivanova, G. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.019 · Cited by 171
Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?
Wade, M., & Wahl, G. M. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0423 · Cited by 170
“Surprisingly, neither Nutlin nor MI-219 appreciably antagonizes the Mdmx/p53 interaction in cancer cell lines, and high Mdmx reduces apoptosis and/or cell cycle arrest induced by these drugs (24, 51, 68, 69).”
BackgroundInfluentialSelf-citationA Human Herpesvirus MicroRNA Inhibits p21 Expression and Attenuates p21-Mediated Cell Cycle Arrest
Gottwein, E., & Cullen, B. R. (2010) · Journal of Virology · doi:10.1128/jvi.00202-10 · Cited by 158
“BL40 cells encode a wild-type (wt) p53 gene, and Nutlin-3 treatment of these cells is known to induce p21 expression (44).”
BackgroundProstate Cancer Biomarkers: From diagnosis to prognosis and precision-guided therapeutics
Adamaki, M., & Zoumpourlis, V. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107932 · Cited by 157
Wong, K., van der Weyden, L., Schott, C. R., Foote, A. K., Constantino‐Casas, F., Smith, S., Dobson, J. M., Murchison, E. P., Wu, H. G., Yeh, I., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08081-1 · Cited by 161
Zhuang, C., Miao, Z., Zhu, L., Dong, G., Guo, Z., Wang, S., Zhang, Y., Wu, Y., Yao, J., Sheng, C., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300969t · Cited by 131
Molecular Basis for the Inhibition of p53 by Mdmx
Popowicz, G. M., Czarna, A., Rothweiler, U., Szwagierczak, A., Krajewski, M., Weber, L., & Holak, T. A. (2007) · Cell Cycle · doi:10.4161/cc.6.19.4740 · Cited by 130
Drugging the undruggable: Transcription therapy for cancer
Yan, C., & Higgins, P. J. (2013) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.11.002 · Cited by 120
Petre, C. E., Sin, S.-H., & Dittmer, D. P. (2007) · Journal of Virology · doi:10.1128/jvi.01757-06 · Cited by 121
Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP
Yuan, Y., Liao, Y.-M., Hsueh, C.-T., & Mirshahidi, H. (2011) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-4-16 · Cited by 132
A Small-Molecule Inhibitor of MDMX Activates p53 and Induces Apoptosis
Wang, H., Ma, X., Ren, S., Buolamwini, J. K., & Yan, C. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0581 · Cited by 117
Quantitative analyses reveal the importance of regulated Hdmx degradation for p53 activation
Wang, Y. V., Wade, M., Wong, E., Li, Y.-C., Rodewald, L. W., & Wahl, G. M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701497104 · Cited by 116
Self-citationVerreault, M., Schmitt, C., Goldwirt, L., Pelton, K., Haidar, S., Levasseur, C., Guehennec, J., Knoff, D., Labussière, M., Marie, Y., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1015 · Cited by 114
Khurana, A., & Shafer, D. A. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s172315 · Cited by 102
Tsvetkov, P., Asher, G., Paz, A., Reuven, N., Sussman, J. L., Silman, I., & Shaul, Y. (2008) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.21614 · Cited by 104
Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer
Patel, S., & Player, M. R. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780802493366 · Cited by 99
MdmX is a substrate for the deubiquitinating enzyme USP2a
Allende-Vega, N., Sparks, A., Lane, D. P., & Saville, M. K. (2010) · Oncogene · doi:10.1038/onc.2009.330 · Cited by 100
Nutlin-3 protects kidney cells during cisplatin therapy by suppressing Bax/Bak activation
Jiang, M., Pabla, N., Murphy, R. F., Yang, T., Yin, X.-M., Degenhardt, K., White, E., & Dong, Z. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m606928200 · Cited by 97
Kitagawa, M., Aonuma, M., Lee, S. H., Fukutake, S., & McCormick, F. P. (2008) · Oncogene · doi:10.1038/onc.2008.164 · Cited by 91
Tabe, Y., Sebasigari, D., Jin, L., Rudelius, M., Davies-Hill, T., Miyake, K., Miida, T., Pittaluga, S., & Raffeld, M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0399 · Cited by 83
MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines
Ohnstad, H. O., Paulsen, E. B., Noordhuis, P., Berg, M., Lothe, R. A., Vassilev, L. T., & Myklebost, O. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-211 · Cited by 77
Kallen, J., Goepfert, A., Blechschmidt, A., Izaac, A., Geiser, M., Tavares, G., Ramage, P., Furet, P., Masuya, K., & Lisztwan, J. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m809096200 · Cited by 71
β-Peptides with improved affinity for hDM2 and hDMX
Harker, E. A., Daniels, D. S., Guarracino, D. A., & Schepartz, A. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.01.039 · Cited by 71
Targeting the MDM2-p53 protein–protein interaction for new cancer therapeutics
Wang, S., Zhao, Y., Bernard, D., Aguilar, A., & Kumar, S. (2012) · Topics in Medicinal Chemistry · doi:10.1007/978-3-642-28965-1_2 · Cited by 72
“Interestingly, in some cancer cell lines, MDM2 inhibitors can induce MDMX degradation, presumably mediated though p53-dependent up-regulation of MDM2 [50, 66, 76], which is known to ubiquitinate and degrade MDMX during DNA damage [77].”
BackgroundIn Silico Improvement of β3-Peptide Inhibitors of p53•hDM2 and p53•hDMX
Michel, J., Harker, E. A., Tirado‐Rives, J., Jorgensen, W. L., & Schepartz, A. (2009) · Journal of the American Chemical Society · doi:10.1021/ja901478e · Cited by 74
Wild type p53 reactivation: From lab bench to clinic
Selivanova, G. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.03.049 · Cited by 65
Forte, E., & Luftig, M. A. (2009) · Journal of Virology · doi:10.1128/jvi.01681-08 · Cited by 65
p53 inactivation by MDM2 and MDMX negative feedback loops in testicular germ cell tumors
Li, B., Cheng, Q., Li, Z., & Chen, J. (2010) · Cell Cycle · doi:10.4161/cc.9.7.11255 · Cited by 64
de Lange, J., Ly, L. V., Lodder, K., Vries, M. V., Teunisse, A. F. A. S., Jager, M. J., & Jochemsen, A. G. (2011) · Oncogene · doi:10.1038/onc.2011.309 · Cited by 68
Multiple p53-independent gene silencing mechanisms define the cellular response to p53 activation
París, R., Henry, R. E., Stephens, S. J., McBryde, M., & Espinosa, J. M. (2008) · Cell Cycle · doi:10.4161/cc.6420 · Cited by 63
Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin‐3 in gastric cancer cells
Endo, S., Yamato, K., Hirai, S., Moriwaki, T., Fukuda, K., Suzuki, H., Abei, M., Nakagawa, I., & Hyodo, I. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2010.01821.x · Cited by 66
Jones, R. J., Bjorklund, C. C., Baladandayuthapani, V., Kuhn, D. J., & Orlowski, R. Z. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0135 · Cited by 58
Small molecule compounds targeting the p53 pathway: are we finally making progress?
Yu, X., Narayanan, S., Vazquez, A., & Carpizo, D. R. (2014) · Apoptosis · doi:10.1007/s10495-014-0990-3 · Cited by 59
Targeting the Ubiquitin-Mediated Proteasome Degradation of p53 for Cancer Therapy
DeVine, T., & Dai, M. (2013) · Current Pharmaceutical Design · doi:10.2174/1381612811319180009 · Cited by 62
Structural and Functional Basis for Therapeutic Modulation of p53 Signaling
Bassett, E. A., Wang, W., Rastinejad, F., & El-Deiry, W. S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1526 · Cited by 57
When the guardian sleeps: Reactivation of the p53 pathway in cancer
Merkel, O., Taylor, N., Prutsch, N., Staber, P. B., Moriggl, R., Turner, S. D., & Kenner, L. (2017) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2017.02.003 · Cited by 65
Phillips, A., Teunisse, A., Lam, S., Lodder, K., Darley, M., Emaduddin, M., Wolf, A., Richter, J., de Lange, J., Verlaan-de Vries, M., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.129726 · Cited by 55
Vaseva, A. V., Yallowitz, A. R., Marchenko, N. D., Xu, S., & Moll, U. M. (2011) · Cell Death & Disease · doi:10.1038/cddis.2011.39 · Cited by 55
Qin, Q., Wang, S., Tan, M., Wang, Z., Luo, D.-M., Zou, B., Liu, Y.-C., Yao, P.-F., & Liang, H. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.09.008 · Cited by 55
Pirh2 RING‐finger E3 ubiquitin ligase: Its role in tumorigenesis and cancer therapy
Jung, Y.-S., Qian, Y., & Chen, X. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.03.052 · Cited by 57
Pharmacological activation of wild-type p53 in the therapy of leukemia
Kojima, K., Ishizawa, J., & Andreeff, M. (2016) · Experimental Hematology · doi:10.1016/j.exphem.2016.05.014 · Cited by 56
Targeting MDMX for Cancer Therapy: Rationale, Strategies, and Challenges
Yu, D.-H., Xu, Z., Mo, S., Li, Y., Cheng, X., & Qin, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01389 · Cited by 54
Role of Mdm4 in drug sensitivity of breast cancer cells
Lam, S., Lodder, K., Teunisse, A. F. A. S., Rabelink, M. J. W. E., Schutte, M., & Jochemsen, A. G. (2010) · Oncogene · doi:10.1038/onc.2009.522 · Cited by 52
Targeting the ubiquitin–proteasome system to activate wild-type p53 for cancer therapy
Allende-Vega, N., & Saville, M. K. (2009) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2009.10.004 · Cited by 52
Ubiquitylation of p53 by the APC/C inhibitor Trim39
Zhang, L., Huang, N.-J., Chen, C., Tang, W., & Kornbluth, S. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1212047110 · Cited by 51
Wang, H., & Yan, C. (2011) · Neoplasia · doi:10.1593/neo.11438 · Cited by 58
Identification of a novel p53-dependent activation pathway of STAT1 by antitumour genotoxic agents
Youlyouz‐Marfak, I., Gachard, N., Clorennec, C. L., Najjar, I., Baran‐Marszak, F., Reminieras, L., May, E., Bornkamm, G. W., Fagard, R., & Feuillard, J. (2007) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402270 · Cited by 50
Toufektchan, E., Lejour, V., Durand, R., Giri, N., Drašković, I., Bardot, B., Laplante, P., Jaber, S., Alter, B. P., Londoño‐Vallejo, A., et al. (2020) · Science Advances · doi:10.1126/sciadv.aay3511 · Cited by 56
Targeting the MDM2/MDM4 Interaction Interface as a Promising Approach for p53 Reactivation Therapy
Pellegrino, M., Mancini, F., Lucà, R., Coletti, A., Giacchè, N., Manni, I., Arisi, I., Florenzano, F., Teveroni, E., Buttarelli, M., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0439 · Cited by 56
Sparks, A., Dayal, S., Das, J., Robertson, P., Ménendez, S., & Saville, M. K. (2013) · Oncogene · doi:10.1038/onc.2013.413 · Cited by 53
BH3 activation blocks Hdmx suppression of apoptosis and cooperates with Nutlin to induce cell death
Wade, M., Rodewald, L. W., Espinosa, J. M., & Wahl, G. M. (2008) · Cell Cycle · doi:10.4161/cc.7.13.6072 · Cited by 48
Self-citationRinaldo, C., Prodosmo, A., Siepi, F., Moncada, A., Sacchi, A., Selivanova, G., & Soddu, S. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0337 · Cited by 51
Chen, X., Qiu, J., Yang, D., Lu, J., Yan, C., Zha, X., & Yin, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078794 · Cited by 47
“finger domain, and a RING finger domain that possesses E3 ligase activity [25–29].”
BackgroundPharmacologic activation of wild-type p53 by nutlin therapy in childhood cancer
Maerken, T. V., Rihani, A., Goethem, A. V., Paepe, A. D., Speleman, F., & Vandesompele, J. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.11.002 · Cited by 51
Soares, J., Raimundo, L., Pereira, N. A. L., dos Santos, D. J. V. A., Pérez, M., Queiróz, G., Leão, M., Santos, M. M. M., & Saraiva, L. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.03.006 · Cited by 46
Cathepsin F Knockdown Induces Proliferation and Inhibits Apoptosis in Gastric Cancer Cells
Ji, C., Zhao, Y., Kou, Y., Shao, H., Guo, L., Bao, C., Jiang, B., Chen, X., Dai, J., Tong, Y., et al. (2017) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504017x14928634401204 · Cited by 46
Chen, W., Yang, K., Zhang, Y.-Z., Lin, Z.-S., Chen, J.-W., Qi, S.-F., Wu, C., Feng, G., Yang, D.-J., Chen, M., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03168-8 · Cited by 46
Merkel, C. A., Soares, R. B. D. S., de Carvalho, A. C. V., Zanatta, D. B., Bajgelman, M. C., Fratini, P., Costanzi-Strauss, E., & Strauss, B. E. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-316 · Cited by 43
Spinnler, C., Hedström, E., Li, H., de Lange, J., Nikulenkov, F., Teunisse, A. F. A. S., Vries, M. V., Grinkevich, V. V., Jochemsen, A. G., & Selivanova, G. (2011) · Cell Death and Differentiation · doi:10.1038/cdd.2011.45 · Cited by 44
Multiplex detection of protein–protein interactions using a next generation luciferase reporter
Verhoef, L. G. G. C., Mattioli, M., Ricci, F., Li, Y., & Wade, M. R. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.11.031 · Cited by 48
Self-citationMDM4 (MDMX) and its Transcript Variants
Mancini, F., Conza, G. D., & Moretti, F. (2009) · Current Genomics · doi:10.2174/138920209787581280 · Cited by 49
Wang, X. D., Su, G. Y., Zhao, C., Qu, F. Z., Wang, P., & Zhao, Y. Q. (2017) · Journal of Ginseng Research · doi:10.1016/j.jgr.2016.12.014 · Cited by 40
Saison-Ridinger, M., DelGiorno, K. E., Zhang, T., Kraus, A., French, R., Jaquish, D., Tsui, C., Erikson, G., Spike, B. T., Shokhirev, M. N., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0189051 · Cited by 38
Self-citationZhou, R., Lu, Z., Liu, K., Guo, J., Liu, J., Zhou, Y., Yang, J., Mi, M., & Xu, H. (2015) · Current Cancer Drug Targets · doi:10.2174/1568009614666141128104642 · Cited by 39
Smith, J. M., Frost, J. R., & Fasan, R. (2014) · Chemical Communications · doi:10.1039/c4cc01199f · Cited by 42
Veerakumarasivam, A., Scott, H. E., Chin, S.-F., Warren, A., Wallard, M. J., Grimmer, D., Ichimura, K., Caldas, C., Collins, V. P., Neal, D. E., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4129 · Cited by 36
ElSawy, K. M., Verma, C. S., Joseph, T. L., Lane, D. P., Twarock, R., & Caves, L. S. D. (2013) · Cell Cycle · doi:10.4161/cc.23511 · Cited by 39
Stiasny, A., Freier, C. P., Kühn, C., Schulze, S., Mayr, D. C., Alexiou, C., Janko, C., Wiest, I., Dannecker, C., Jeschke, U., et al. (2017) · Oncology Letters · doi:10.3892/ol.2017.6752 · Cited by 37
CARPs enhance p53 turnover by degrading 14-3-3σ and stabilizing MDM2
Yang, W., Dicker, D. T., Chen, J., & El‐Deiry, W. S. (2008) · Cell Cycle · doi:10.4161/cc.7.5.5701 · Cited by 41
Dudgeon, D. D., Shinde, S. S., Hua, Y., Shun, T. Y., Lazo, J. S., Strock, C. J., Giuliano, K. A., Taylor, D. L., Johnston, P. A., & Johnston, P. A. (2010) · SLAS DISCOVERY · doi:10.1177/1087057110375304 · Cited by 37
High Mdm4 levels suppress p53 activity and enhance its half-life in acute myeloid leukaemia
Tan, B. X., Khoo, K. H., Lim, T. M., & Lane, D. P. (2013) · Oncotarget · doi:10.18632/oncotarget.1559 · Cited by 36
Review on Canine Oral Melanoma: An Undervalued Authentic Genetic Model of Human Oral Melanoma?
Palma, S. D., McConnell, A., Verganti, S., & Starkey, M. (2021) · Veterinary Pathology · doi:10.1177/0300985821996658 · Cited by 40
Abnormal MDMX degradation in tumor cells due to ARF deficiency
Li, X., Gilkes, D., Li, B., Cheng, Q., Pernazza, D., Lawrence, H., Lawrence, N., & Chen, J. (2012) · Oncogene · doi:10.1038/onc.2011.534 · Cited by 32
“Owing to structural differences, current inhibitors of MDM2 have negligible effects on MDMXp53 binding, and are thus suboptimal for p53 activation in cells overexpressing MDMX (Hu et al., 2006; Patton et al., 2006; Wade et al., 2006; Shangary et al., 2008).”
InfluentialInhibitors of MDM2 and MDMX: A Structural Perspective
Riedinger, C., & McDonnell, J. M. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.75 · Cited by 37
Stochastic Modeling and Simulation of the p53-MDM2/MDMX Loop
Cai, X., & Yuan, Z.-M. (2009) · Journal of Computational Biology · doi:10.1089/cmb.2008.0231 · Cited by 34
Dudgeon, D. D., Shinde, S. N., Shun, T. Y., Lazo, J. S., Strock, C. J., Giuliano, K. A., Taylor, D. L., Johnston, P. A., & Johnston, P. A. (2010) · Assay and Drug Development Technologies · doi:10.1089/adt.2010.0281 · Cited by 37
p53 binds the mdmx mRNA and controls its translation
Tournillon, A.-S., López, I., Malbert-Colas, L., Findakly, S., Naski, N., Olivares‐Illana, V., Karakostis, K., Vojtěšek, B., Nylander, K., & Fåhræus, R. (2016) · Oncogene · doi:10.1038/onc.2016.236 · Cited by 33
Targeting snoRNAs as an emerging method of therapeutic development for cancer.
Zhang, D., Zhou, J., Gao, J., Wu, R.-Y., Huang, Y., Jin, Q., Chen, J., Tang, W., & Yan, L. (2019) · PubMed Central · Cited by 35
Novel Pathways and Molecular Targets for the Treatment of Sarcoma
Frith, A. E., Hirbe, A. C., & Tine, B. A. V. (2013) · Current Oncology Reports · doi:10.1007/s11912-013-0319-3 · Cited by 34
Macchiarulo, A., Giacchè, N., Carotti, A., Baroni, M., Cruciani, G., & Pellicciari, R. (2008) · Journal of Chemical Information and Modeling · doi:10.1021/ci800146m · Cited by 33
Merlino, F., Daniele, S., Pietra, V. L., Maro, S. D., Leva, F. S. D., Brancaccio, D., Tomassi, S., Giuntini, S., Cerofolini, L., Fragai, M., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00004 · Cited by 28
Palani, C. D., Beck, J. F., & Sonnemann, J. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9510-7 · Cited by 30
Kan, C. E., Patton, J. T., Stark, G. R., & Jackson, M. W. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0259 · Cited by 29
Calculation of hot spots for protein–protein interaction in p53/PMI‐MDM2/MDMX complexes
Huang, D., Qi, Y., Song, J., & Zhang, J. Z. H. (2018) · Journal of Computational Chemistry · doi:10.1002/jcc.25592 · Cited by 27
Roh, J.-L., Kim, E. H., Park, H., & Park, J. Y. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.488 · Cited by 26
Metadata
- Authors
- Wade, M., Wong, E. T., Tang, M., Stommel, J. M., & Wahl, G. M.
- Affiliations
- Salk Institute for Biological Studies (US)
- Corresponding author
- Wahl, Geoffrey M.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2006-11
- Volume
- 281
- Issue
- 44
- Pages
- 33036-33044
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2103069797
- Cited by
- 163
- References
- 57
- Citations by year
- 2025: 2 · 2024: 4 · 2023: 11 · 2022: 1 · 2021: 2 · 2020: 8 · 2019: 4 · 2018: 3 · 2017: 8 · 2016: 9 · 2015: 7 · 2014: 8 · 2013: 13 · 2012: 13
- FWCI
- 7.80
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 5082 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (CA61449, R01CA061449)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Keywords
- HDMX, MDM2, p53 activation, nutlin, apoptosis, caspase-3, p53 transactivation, cancer cell lines, shRNA knockdown
- MeSH terms
- Humans, Imidazoles, Neoplasms, Nuclear Proteins, Piperazines, Protein Binding, Proto-Oncogene Proteins, Down-Regulation, Tumor Suppressor Protein p53, Apoptosis, Cell Cycle Proteins, RNA Interference, Cell Line, Tumor, Caspase 3
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.